Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Stopped early · Phase 3
Conditions studied: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
In brief
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous balixafortide given with eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or Metastatic Breast Cancer.
Key facts
- Study ID
- NCT03786094
- Run by
- Spexis AG
- People needed
- 432
- Starts
- 2019-05-30
- Expected to finish
- 2021-10-19
- Last updated by the study team
- 2023-11-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cedars-Sinai Medical Center — Los Angeles, California, United States
- UCSF Mount Zion Cancer Center — San Francisco, California, United States
- Stanford Cancer Center South Bay — San Jose, California, United States
- Norwalk Hospital — Norwalk, Connecticut, United States
- Florida Cancer Specialists SOUTH - SCRI - PPDS — Fort Myers, Florida, United States
- Orlando Health — Orlando, Florida, United States
- Florida Cancer Specialists NORTH - SCRI - PPDS — St. Petersburg, Florida, United States
- Florida Cancer Specialists PAN - SCRI - PPDS — Tallahassee, Florida, United States
- Tallahassee Memorial HealthCare — Tallahassee, Florida, United States
- Florida Cancer Specialists EAST - SCRI - PPDS — West Palm Beach, Florida, United States
- University Cancer and Blood Center, LLC — Athens, Georgia, United States
- Piedmont Cancer Institute PC — Atlanta, Georgia, United States
- Orchard Healthcare Research Inc — Skokie, Illinois, United States
- Herbert-Herman Cancer Center, Sparrow Hospital — Lansing, Michigan, United States
- Virginia Piper Cancer Institute — Minneapolis, Minnesota, United States
- Saint Luke's Cancer Institute 150 Entrance — Kansas City, Missouri, United States
- HCA Midwest Health - SCRI - PPDS — Kansas City, Missouri, United States
- Mercy Research Oncology — St Louis, Missouri, United States
- CHI Health St. Francis — Grand Island, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Queens Hospital Cancer Center — New York, New York, United States
- OHSU Knight Cancer Institute Hematology Oncology — Portland, Oregon, United States
- Magee Women's Hospital — Pittsburgh, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- California Cancer Associates for Research and Excellence — Fresno, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.